# OnCo record sinonasal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/sinonasal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "sinonasal" ;
  schema:name "Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)"@en ;
  schema:alternateName "Sinonasal cancer"@en, "Esthesioneuroblastoma"@en, "Olfactory neuroblastoma"@en, "Sinonasal undifferentiated carcinoma"@en, "SNUC"@en, "Paranasal sinus cancer"@en ;
  schema:description "Cancers of the nose and sinuses are a mixed group, from squamous carcinoma to the nerve-derived esthesioneuroblastoma and the aggressive undifferentiated carcinoma SNUC. Surgery through the nose with an endoscope followed by precise radiotherapy has replaced disfiguring open operations, and giving chemotherapy first to see who responds now guides how SNUC is treated."@en ;
  schema:url <https://onco.cc/cancers/sinonasal/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Esthesioneuroblastoma> ;
  schema:citation <https://www.cancer.gov/types/head-and-neck/patient/adult/paranasal-sinus-treatment-pdq>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437>, <https://doi.org/10.1001/jamaoncol.2018.5526> ;
  onco:tag "nci-coverage", "rare", "head-and-neck" ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/idh/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/enasidenib/> ;
  onco:pathways <https://onco.cc/pathways/idh-2hg/>, <https://onco.cc/pathways/swi-snf-chromatin/> ;
  onco:terms <https://onco.cc/terms/head-neck-subsites/>, <https://onco.cc/terms/hpv-status/>, <https://onco.cc/terms/rare-cancers/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chen-jama-oncol/> ;
  onco:pipeline <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/enasidenib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/enasidenib/> .